3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Leiomyosarcoma
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Breast Neoplasms
1
Interventions
Specimen Handling
9
Paclitaxel
7
Magnetic Resonance Spectroscopy
6
Carboplatin
6
Biopsy
6
Nivolumab
5
pembrolizumab
3
olaparib
3
X-Rays
3
durvalumab
2
ceralasertib
2
cediranib
2
Taxes
2
Immunoglobulin G
2
trastuzumab deruxtecan
1
sargramostim
1
rucaparib
1
ribociclib
1
rebastinib
1
pelcitoclax
1
pazopanib
1
pamiparib
1
liposomal doxorubicin
1
cobimetinib
1
capivasertib
1
cabozantinib
1
belinostat
1
atezolizumab
1
apatinib
1
Trabectedin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinosarcoma
×
rucaparib
×
Sarcoma
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts